Silence Therapeutics Plc Stock Performance
| SLN Stock | USD 5.59 0.50 9.82% |
On a scale of 0 to 100, Silence Therapeutics holds a performance score of 10. The entity has a beta of 0.0039, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Silence Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Silence Therapeutics is expected to be smaller as well. Please check Silence Therapeutics' maximum drawdown, as well as the relationship between the expected short fall and rate of daily change , to make a quick decision on whether Silence Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Silence Therapeutics PLC are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady essential indicators, Silence Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 9.82 | Five Day Return 6.48 | Year To Date Return (22.25) | Ten Year Return (71.33) | All Time Return (71.33) |
1 | Acquisition by Griffiths Richard Ian of 55766 shares of Silence Therapeutics at 4.07 subject to Rule 16b-3 | 05/15/2025 |
2 | Acquisition by Griffiths Richard Ian of 37023 shares of Silence Therapeutics at 4.01 subject to Rule 16b-3 | 05/16/2025 |
3 | Acquisition by Griffiths Richard Ian of 26000 shares of Silence Therapeutics at 4.07 subject to Rule 16b-3 | 05/19/2025 |
4 | Acquisition by Griffiths Richard Ian of 19174 shares of Silence Therapeutics at 5.04 subject to Rule 16b-3 | 05/22/2025 |
5 | Acquisition by Griffiths Richard Ian of 26669 shares of Silence Therapeutics at 4.91 subject to Rule 16b-3 | 05/23/2025 |
6 | Acquisition by Griffiths Richard Ian of 50000 shares of Silence Therapeutics at 5.13 subject to Rule 16b-3 | 05/27/2025 |
7 | Acquisition by Griffiths Richard Ian of 9169 shares of Silence Therapeutics at 5.11 subject to Rule 16b-3 | 05/28/2025 |
8 | Acquisition by Griffiths Richard Ian of 305 shares of Silence Therapeutics at 5.15 subject to Rule 16b-3 | 06/12/2025 |
9 | Acquisition by Griffiths Richard Ian of 31399 shares of Silence Therapeutics at 5.29 subject to Rule 16b-3 | 06/17/2025 |
10 | Acquisition by Griffiths Richard Ian of 049 shares of Silence Therapeutics at 5.69 subject to Rule 16b-3 | 06/18/2025 |
11 | Acquisition by Griffiths Richard Ian of 20977 shares of Silence Therapeutics at 5.84 subject to Rule 16b-3 | 06/20/2025 |
12 | Acquisition by Griffiths Richard Ian of 26624 shares of Silence Therapeutics at 6.12 subject to Rule 16b-3 | 06/24/2025 |
13 | Acquisition by Griffiths Richard Ian of 657 shares of Silence Therapeutics at 5.91 subject to Rule 16b-3 | 06/26/2025 |
14 | Acquisition by Griffiths Richard Ian of 7937 shares of Silence Therapeutics at 5.65 subject to Rule 16b-3 | 07/07/2025 |
15 | Acquisition by Griffiths Richard Ian of 24387 shares of Silence Therapeutics at 5.94 subject to Rule 16b-3 | 07/08/2025 |
16 | Acquisition by Griffiths Richard Ian of 30133 shares of Silence Therapeutics at 6.0 subject to Rule 16b-3 | 07/09/2025 |
17 | Acquisition by Griffiths Richard Ian of 28000 shares of Silence Therapeutics at 6.43 subject to Rule 16b-3 | 07/11/2025 |
18 | Acquisition by Griffiths Richard Ian of 43293 shares of Silence Therapeutics at 6.4 subject to Rule 16b-3 | 07/15/2025 |
19 | Acquisition by Griffiths Richard Ian of 22435 shares of Silence Therapeutics at 6.04 subject to Rule 16b-3 | 07/21/2025 |
20 | Acquisition by Griffiths Richard Ian of 2910 shares of Silence Therapeutics at 6.09 subject to Rule 16b-3 | 07/22/2025 |
21 | Acquisition by Griffiths Richard Ian of 14559 shares of Silence Therapeutics at 6.2 subject to Rule 16b-3 | 07/29/2025 |
22 | Acquisition by Griffiths Richard Ian of 8923 shares of Silence Therapeutics at 6.14 subject to Rule 16b-3 | 07/30/2025 |
23 | Acquisition by Griffiths Richard Ian of 14342 shares of Silence Therapeutics at 6.18 subject to Rule 16b-3 | 07/31/2025 |
24 | Insider Buyers At Silence Therapeutics Likely Disappointed With 13 percent Slide | 08/07/2025 |
25 | Silence Therapeutics plc Second-Quarter Results Heres What Analysts Are Forecasting For This Year | 08/12/2025 |
| Begin Period Cash Flow | 68.8 M | |
| Total Cashflows From Investing Activities | -22 M |
Silence Therapeutics Relative Risk vs. Return Landscape
If you would invest 401.00 in Silence Therapeutics PLC on May 15, 2025 and sell it today you would earn a total of 158.00 from holding Silence Therapeutics PLC or generate 39.4% return on investment over 90 days. Silence Therapeutics PLC is generating 0.6527% of daily returns assuming volatility of 4.7239% on return distribution over 90 days investment horizon. In other words, 42% of stocks are less volatile than Silence, and above 87% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Silence Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Silence Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Silence Therapeutics PLC, and traders can use it to determine the average amount a Silence Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1382
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SLN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.72 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.65 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Silence Therapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Silence Therapeutics by adding it to a well-diversified portfolio.
Silence Therapeutics Fundamentals Growth
Silence Stock prices reflect investors' perceptions of the future prospects and financial health of Silence Therapeutics, and Silence Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Silence Stock performance.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.91) % | ||||
| Operating Margin | (90.48) % | ||||
| Current Valuation | 102.29 M | ||||
| Shares Outstanding | 47.23 M | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 9.72 X | ||||
| Revenue | 43.26 M | ||||
| Gross Profit | 21.35 M | ||||
| EBITDA | (48.99 M) | ||||
| Net Income | (45.31 M) | ||||
| Cash And Equivalents | 51.56 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 117 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.76 X | ||||
| Book Value Per Share | 1.99 X | ||||
| Cash Flow From Operations | (67.64 M) | ||||
| Earnings Per Share | (1.68) X | ||||
| Market Capitalization | 264.04 M | ||||
| Total Asset | 202.63 M | ||||
| Retained Earnings | (474.04 M) | ||||
| Working Capital | 170.54 M | ||||
About Silence Therapeutics Performance
By examining Silence Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Silence Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Silence Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (633.75) | (602.07) | |
| Return On Tangible Assets | (0.23) | (0.25) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | (0.34) | (0.35) |
Things to note about Silence Therapeutics PLC performance evaluation
Checking the ongoing alerts about Silence Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Silence Therapeutics PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Silence Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 43.26 M. Reported Net Loss for the year was (45.31 M) with profit before taxes, overhead, and interest of 21.35 M. | |
| Silence Therapeutics PLC has about 51.56 M in cash with (67.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72. | |
| Roughly 24.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering |
- Analyzing Silence Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Silence Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Silence Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Silence Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Silence Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Silence Therapeutics' stock. These opinions can provide insight into Silence Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.68) | Revenue Per Share | Quarterly Revenue Growth (0.70) | Return On Assets | Return On Equity |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.